Methadone clinics are now being evaluated with new standards.
In 2024, amid criticism from patient groups and increased examination by lawmakers, the federal government unveiled a comprehensive update of regulations governing these clinics. This long-anticipated move aims to reshape how methadone clinics function.
The updated regulations provide increased flexibility regarding “take-home” medications and emphasize that while counseling should be available, it should not be a mandatory requirement for patients to receive their medication.
A critical question has always been whether clinics and their overseeing state agencies would embrace a significant cultural transformation, rather than just the scale of regulatory changes. Recently, there are signs that a shift is occurring. Data from industry groups and the federal government shows that a notable portion of opioid treatment programs, often known as OTPs, have adopted substantial changes.
“A significant majority of OTPs have incorporated the changes,” said Mark Parrino, president of the American Association for the Treatment of Opioid Dependence, a New York-based organization representing methadone clinics. “I’d say more than 75% of the programs have, in fact, provided more take-home medication … and the result has been, as the study captured, that retention in treatment has significantly increased.”
Methadone, a potent medication used to manage withdrawal symptoms and stabilize individuals addicted to opioids, stands as the most effective treatment for opioid addiction. Despite its efficacy, methadone has long been isolated from the broader U.S. medical system. Traditionally, clinics required daily in-person visits for patients to receive their doses, creating significant barriers for those with jobs, families, or who lived at a distance.
However, since 2020, methadone clinics have rapidly evolved. During the Covid-19 pandemic, to prevent disease spread, the Substance Abuse and Mental Health Services Administration allowed clinics to provide multiple weeks of “take-home” medication, enabling patients to manage their treatment from home.
The 2024 regulations have made many of these changes permanent, urging clinics and state-level bodies to abandon punitive and rigid practices. Industry leaders have begun to accept this shift, recognizing that quality care can be delivered even when patients are not present in person daily.
Dustin Mets, CEO of CompDrug, an Ohio-based behavioral health clinic, noted during a recent SAMHSA webinar that the new regulations have shifted the focus from mandating to motivating.
“OTPs are getting more comfortable with exercising greater discretion in balancing safety, patient preference, and other factors, in ways that we frankly didn’t have the leeway to do before,” he said. “We’re discovering that physical presence is a rather poor proxy for a strong therapeutic relationship.”
Mets, along with other federal officials and industry leaders, referred to a survey by AATOD, Parrino’s organization, and the National Association of Addiction Treatment Providers.
The survey’s data, however, was limited, with responses from 241 clinics, which represent just over 10% of the nation’s opioid treatment programs.
The outcomes were nonetheless encouraging. Mets reported that the proportion of patients remaining in treatment three months after starting care rose by an average of 17% following the implementation of these changes.
More broadly, over 70% of the surveyed clinics had adopted at least half of SAMHSA’s recommended practices. These practices include enhanced access to take-home medication and higher initial treatment doses to help patients avoid withdrawal, thus reducing the likelihood of continued illicit substance use.
The reforms also prompted clinics to offer and promote counseling without withholding medication from those who decline it. According to the survey, about two-thirds of state opioid treatment authorities, which oversee individual clinics, have adopted this approach.
Similarly, the new SAMHSA guidelines suggest using drug testing as a factor in clinical decisions rather than automatically revoking take-home doses or penalizing patients who test positive for substances like heroin or fentanyl.
Two particularly outdated rules were also abolished: one requiring patients to have been addicted to opioids for over a year before seeking treatment at a methadone clinic, and another mandating that patients must have tried and failed other treatments twice before being admitted.
Despite these changes, not all industry experts agree with the positive portrayal seen in a recent SAMHSA webinar. Some argue that the survey results could be skewed by selection bias, suggesting that clinics eager to report changes were more likely to respond.
“I have it on good authority that most of the larger providers have not been proactive whatsoever with implementing those changes,” said Aaron Ferguson, a prominent figure in the Liberate Methadone movement, which supports allowing doctors to prescribe methadone directly to patients rather than through clinics. “I think that SAMHSA’s report is a misrepresentation of the field, by and large. They only polled a small percentage of OTPs.”
Ferguson also highlighted potential geographic disparities, noting that clinics in states with more progressive methadone cultures, such as New York, are more likely to adopt the changes compared to those in conservative states.
Efforts by clinics to gather patient feedback tend to focus on “compliant” patients who already adhere to clinic policies and have achieved stability, Ferguson said, ironically leaving those who might benefit most from flexible policies underrepresented.
He emphasized that changes in clinic culture are more likely to result from truly understanding patients’ needs and preferences rather than from regulatory updates.
“The culture is going to shift as a result of people realizing what patients want and need, but they’re not hearing the full story,” Ferguson said. “They’re going to have to start really taking a hard look at why this treatment is not reaching people that it should be.”
STAT’s coverage of chronic health issues is supported by a grant from Bloomberg Philanthropies. Our financial supporters are not involved in any decisions about our journalism.
